Patients received a symptom-triggered Clinical Institute Withdrawal Assessment protocol with lorazepam and were randomized to dexmedetomidine @ g/kg/hr ( high dose ) , @ g/kg/hr ( low dose ) , or placebo as adjunctive therapy for up to @ days or resolution of withdrawal symptoms .